Deborah A. Thomas

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ.